Press releases
- Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual Meeting
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
- Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
- Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC
- Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
- Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
- Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
- Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
- Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI
More ▼
Key statistics
As of last trade Mirum Pharmaceuticals Inc (08D:DEU) traded at 22.60, 4.63% above its 52-week low of 21.60, set on Apr 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 22.40 |
---|---|
High | 22.80 |
Low | 22.20 |
Bid | 22.40 |
Offer | 23.20 |
Previous close | 22.40 |
Average volume | 55.00 |
---|---|
Shares outstanding | 47.13m |
Free float | 45.96m |
P/E (TTM) | -- |
Market cap | 1.17bn USD |
EPS (TTM) | -3.82 USD |
Data delayed at least 15 minutes, as of May 28 2024.
More ▼